Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 97 articles:
HTML format
Text format



Single Articles


    February 2017
  1. GARCIA-ARRIAZA J, Perdiguero B, Heeney JL, Seaman MS, et al
    HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell i
    J Virol. 2017 Feb 8. pii: JVI.02182-16. doi: 10.1128/JVI.02182.
    PubMed     Text format     Abstract available


  2. JIANG W, Wang S, Chen H, Ren H, et al
    A bivalent heterologous DNA-virus-like particles prime-boost vaccine elicits broad protection against both groups 1 and 2 influenza A viruses.
    J Virol. 2017 Feb 8. pii: JVI.02052-16. doi: 10.1128/JVI.02052.
    PubMed     Text format     Abstract available


  3. NASAR F, Matassov D, Seymour RL, Latham T, et al
    Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Feb 1. pii: JVI.01729-16. doi: 10.1128/JVI.01729.
    PubMed     Text format     Abstract available


  4. HALEY SL, Tzvetkov EP, Meuwissen S, Plummer JR, et al
    Targeting Vaccine-induced Extrafollicular Pathway of B cell Differentiation Improves Rabies Post-exposure Prophylaxis.
    J Virol. 2017 Feb 1. pii: JVI.02435-16. doi: 10.1128/JVI.02435.
    PubMed     Text format     Abstract available


  5. SCHNEIDER-OHRUM K, Cayatte C, Snell Bennett A, Manohar Rajani G, et al
    Immunization with low doses of recombinant post-fusion or pre-fusion RSV F primes for vaccine-enhanced disease in the cotton rat model independent of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant.
    J Virol. 2017 Feb 1. pii: JVI.02180-16. doi: 10.1128/JVI.02180.
    PubMed     Text format     Abstract available


    January 2017
  6. ROYER DJ, Carr MM, Chucair-Elliott AJ, Halford WP, et al
    Impact of type 1 interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex virus type 1 vaccine in mice.
    J Virol. 2017 Jan 25. pii: JVI.02342-16. doi: 10.1128/JVI.02342.
    PubMed     Text format     Abstract available


  7. TANG X, Yang Y, Xia X, Zhang C, et al
    Recombinant adenoviruses displaying matrix 2 ectodomain epitopes (M2e) on their fiber proteins as universal influenza vaccines.
    J Virol. 2017 Jan 18. pii: JVI.02462-16. doi: 10.1128/JVI.02462.
    PubMed     Text format     Abstract available


  8. LI Y, Zhou M, Luo Z, Zhang Y, et al
    Overexpression of IL-7 extends the humoral immune response induced by rabies vaccination.
    J Virol. 2017 Jan 18. pii: JVI.02324-16. doi: 10.1128/JVI.02324.
    PubMed     Text format     Abstract available


  9. KIM SM, Kim YI, Park SJ, Kim EH, et al
    Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy.
    J Virol. 2017 Jan 11. pii: JVI.01693-16. doi: 10.1128/JVI.01693.
    PubMed     Text format     Abstract available


  10. NAITO T, Mori K, Ushirogawa H, Takizawa N, et al
    Generation of a genetically stable high-fidelity influenza vaccine strain.
    J Virol. 2017 Jan 4. pii: JVI.01073-16. doi: 10.1128/JVI.01073.
    PubMed     Text format     Abstract available


    December 2016
  11. NIVARTHI UK, Kose N, Sapparapu G, Widman D, et al
    Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination.
    J Virol. 2016 Dec 28. pii: JVI.02041-16. doi: 10.1128/JVI.02041.
    PubMed     Text format     Abstract available


  12. DAI A, Cao S, Dhungel P, Luan Y, et al
    Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs During Vaccinia Virus-induced Host Shutoff.
    J Virol. 2016 Dec 21. pii: JVI.01858-16. doi: 10.1128/JVI.01858.
    PubMed     Text format     Abstract available


  13. LEE J, Hashimoto M, Im SJ, Araki K, et al
    Adenovirus serotype 5 vaccination results in suboptimal CD4 T helper 1 responses in mice.
    J Virol. 2016 Dec 21. pii: JVI.01132-16. doi: 10.1128/JVI.01132.
    PubMed     Text format     Abstract available


  14. EDUARDO-CORREIA B, Martinez-Romero C, Garcia-Sastre A, Guerra S, et al
    Correction for Eduardo-Correia et al., ISG15 Is Counteracted by Vaccinia Virus E3 Protein and Controls the Proinflammatory Response against Viral Infection.
    J Virol. 2016;90:11280.
    PubMed     Text format    


  15. ANGELO MA, Grifoni A, O'Rourke PH, Sidney J, et al
    Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity.
    J Virol. 2016 Dec 14. pii: JVI.02147.
    PubMed     Text format     Abstract available


  16. NOGALES A, Rodriguez L, Chauche C, Huang K, et al
    A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine.
    J Virol. 2016 Dec 7. pii: JVI.02211.
    PubMed     Text format     Abstract available


  17. CONE KR, Kronenberg ZN, Yandell M, Elde NC, et al
    Emergence of a viral RNA polymerase variant during gene copy number amplification promotes rapid evolution of vaccinia virus.
    J Virol. 2016 Dec 7. pii: JVI.01428.
    PubMed     Text format     Abstract available


  18. SHAW JM, Miller-Novak LK, Mohanram V, McKinnon K, et al
    Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4hi Plasma Cells and Plasmablasts in Vaccinated, SIV-Infected Rhesus Macaques with Low and High Viremia.
    J Virol. 2016 Dec 7. pii: JVI.01727.
    PubMed     Text format     Abstract available


  19. KASTURI SP, Kozlowski PA, Nakaya HI, Burger MC, et al
    Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5alpha restrictive macaques.
    J Virol. 2016 Dec 7. pii: JVI.01844.
    PubMed     Text format     Abstract available


    November 2016
  20. WANG Z, Li M, Zhou M, Zhang Y, et al
    A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells.
    J Virol. 2016 Nov 16. pii: JVI.01956.
    PubMed     Text format     Abstract available


  21. WIRBLICH C, Coleman CM, Kurup D, Abraham TS, et al
    One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus.
    J Virol. 2016 Nov 2. pii: JVI.02040.
    PubMed     Text format     Abstract available


  22. CROSBY CM, Matchett WE, Anguiano-Zarate SS, Parks CA, et al
    Replicating Single-cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.
    J Virol. 2016 Nov 2. pii: JVI.00720.
    PubMed     Text format     Abstract available


    October 2016
  23. CELMA CC, Stewart M, Wernike K, Eschbaumer M, et al
    Replication-deficient particles: New insights into the next generation of bluetongue virus vaccines.
    J Virol. 2016 Oct 26. pii: JVI.01892.
    PubMed     Text format     Abstract available


  24. LOGAN M, Law J, Wong JA, Hockman D, et al
    Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG.
    J Virol. 2016 Oct 19. pii: JVI.01552.
    PubMed     Text format     Abstract available


    September 2016
  25. ROUXEL RN, Tafalla C, Merour E, Leal E, et al
    Attenuated Infectious Hematopoietic Necrosis Virus (IHNV) with rearranged gene order as potential vaccine.
    J Virol. 2016 Sep 28. pii: JVI.01024.
    PubMed     Text format     Abstract available


  26. LI D, von Schaewen M, Wang X, Tao W, et al
    Altered glycosylation patterns increase immunogenicity of a subunit HCV vaccine inducing neutralizing antibodies which confer protection in mice.
    J Virol. 2016 Sep 14. pii: JVI.01462.
    PubMed     Text format     Abstract available


  27. ZOLLA-PAZNER S, Powell R, Yahyaei S, Williams C, et al
    RATIONALLY-DESIGNED VACCINES TARGETING THE V2 REGION OF HIV-1 gp120 INDUCE A FOCUSED, CROSS CLADE-REACTIVE, BIOLOGICALLY FUNCTIONAL ANTIBODY RESPONSE.
    J Virol. 2016 Sep 14. pii: JVI.01403.
    PubMed     Text format     Abstract available


  28. COSTA M, Pollara J, Edwards RW, Seaman M, et al
    Fc receptor mediated activities by Env-specific human mAbs generated from volunteers receiving the DNA prime-protein boost HIV vaccine DP6-001.
    J Virol. 2016 Sep 14. pii: JVI.01458.
    PubMed     Text format     Abstract available


    August 2016
  29. HARRISON K, Haga IR, Pechenick Jowers T, Jasim S, et al
    Vaccinia virus uses retromer-independent cellular retrograde transport pathways to facilitate the wrapping of intracellular mature virions during viral morphogenesis.
    J Virol. 2016 Aug 31. pii: JVI.01464.
    PubMed     Text format     Abstract available


  30. NGO T, Mirzakhanyan Y, Moussatche N, Gershon PD, et al
    Protein primary structure of the Vaccinia virion at increased resolution.
    J Virol. 2016 Aug 24. pii: JVI.01042.
    PubMed     Text format     Abstract available


    July 2016
  31. IYER SS, Gangadhara S, Victor B, Shen X, et al
    Virus-like particles displaying trimeric SIV envelope gp160 enhance the breadth of DNA/MVA SIV vaccine induced antibody responses in rhesus macaques.
    J Virol. 2016 Jul 27. pii: JVI.01163.
    PubMed     Text format     Abstract available


  32. SIVAN G, Weisberg AS, Americo JL, Moss B, et al
    Retrograde Transport from Early Endosomes to the Trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virions.
    J Virol. 2016 Jul 27. pii: JVI.01114.
    PubMed     Text format     Abstract available


  33. LIU WC, Jan JT, Huang YJ, Chen TH, et al
    Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza hemagglutinin proteins for vaccine design.
    J Virol. 2016 Jul 20. pii: JVI.00880.
    PubMed     Text format     Abstract available


  34. ZHOU B, Meliopoulos VA, Wang W, Lin X, et al
    Reversion of Cold-adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.
    J Virol. 2016 Jul 20. pii: JVI.00163.
    PubMed     Text format     Abstract available


  35. GACH JS, Venzon D, Vaccari M, Keele BF, et al
    The relationship between vaccine-induced antibody capture of infectious virus and infection outcomes following low-dose, repeated rectal challenge with SIVmac251.
    J Virol. 2016 Jul 20. pii: JVI.00812.
    PubMed     Text format     Abstract available


  36. DEPLEDGE DP, Yamanishi K, Gomi Y, Gershon A, et al
    Deep-sequencing of distinct preparations of the live-attenuated VZV vaccine reveals a conserved core of attenuating SNPs.
    J Virol. 2016 Jul 20. pii: JVI.00998.
    PubMed     Text format     Abstract available


    June 2016
  37. CHOI KY, Root M, McGregor A
    A Novel Non-Replication Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.
    J Virol. 2016 Jun 22. pii: JVI.00283.
    PubMed     Text format     Abstract available


  38. LIU R, Moss B
    Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR/Cas9 Knock-Out Cell Lines and Vaccinia Virus Mutants.
    J Virol. 2016 Jun 22. pii: JVI.00869.
    PubMed     Text format     Abstract available


  39. ROSTAD CA, Stobart CC, Gilbert BE, Pickles RJ, et al
    A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats.
    J Virol. 2016 Jun 8. pii: JVI.00012.
    PubMed     Text format     Abstract available


  40. LULLA V, Lulla A, Wernike K, Aebischer A, et al
    Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes.
    J Virol. 2016 Jun 8. pii: JVI.00548.
    PubMed     Text format     Abstract available


  41. JENSEN K, Nabi R, Van Rompay KK, Robichaux S, et al
    Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant rhesus macaques.
    J Virol. 2016 Jun 1. pii: JVI.00481.
    PubMed     Text format     Abstract available


    May 2016
  42. KO EJ, Lee YT, Kim KH, Jung YJ, et al
    MF59 adjuvant effects on inducing isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells.
    J Virol. 2016 May 25. pii: JVI.00339.
    PubMed     Text format     Abstract available


  43. LEE YT, Ko EJ, Lee Y, Lee YN, et al
    CD47 plays a role as a negative regulator in inducing protective immune responses to vaccination against influenza virus.
    J Virol. 2016 May 18. pii: JVI.00605.
    PubMed     Text format     Abstract available


  44. LARSEN IV, Clausius H, Kolb AW, Brandt CR, et al
    Both CD8+ and CD4+ T-Cells Contribute to Corneal Clouding and Viral Clearance Following Vaccinia Virus Infection in C57BL/6 Mice.
    J Virol. 2016 May 11. pii: JVI.00570.
    PubMed     Text format     Abstract available


  45. BOXUS M, Fochesato M, Miseur A, Mertens E, et al
    Broad cross protection is induced by a human papillomavirus vaccine composed of L1/L2 chimeric virus-like particles in preclinical models.
    J Virol. 2016 May 4. pii: JVI.00449.
    PubMed     Text format     Abstract available


  46. NOTARIO L, Alari-Pahissa E, de Molina A, Lauzurica P, et al
    CD69 deficiency enhances the host response to Vaccinia virus infection through altered NK cell homeostasis.
    J Virol. 2016 May 4. pii: JVI.00550.
    PubMed     Text format     Abstract available


    April 2016
  47. NOGALES A, DeDiego ML, Topham DJ, Martinez-Sobrido L, et al
    Rearrangement of influenza virus spliced segments for the development of live attenuated vaccines.
    J Virol. 2016 Apr 27. pii: JVI.00410.
    PubMed     Text format     Abstract available


  48. WIDJAJA I, Wicht O, Luytjes W, Leenhouts K, et al
    Characterization of epitope-specific anti-RSV antibody responses after natural infection and after vaccination with formalin-inactivated RSV.
    J Virol. 2016 Apr 20. pii: JVI.00235.
    PubMed     Text format     Abstract available


  49. KOROTKOVA EA, Gmyl AP, Yakovenko ML, Ivanova OE, et al
    A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin-2 vaccine virus.
    J Virol. 2016 Apr 20. pii: JVI.00277.
    PubMed     Text format     Abstract available


  50. KRISTENSEN AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, et al
    Antibody responses with Fc-mediated functions after trivalent influenza vaccination of HIV-infected subjects.
    J Virol. 2016 Apr 6. pii: JVI.00285.
    PubMed     Text format     Abstract available


  51. TAYLOR A, Melton JV, Herrero LJ, Thaa B, et al
    Effects of an In-Frame Deletion of the 6k Gene Locus from the Genome of Ross River Virus.
    J Virol. 2016;90:4150-9.
    PubMed     Text format     Abstract available


    March 2016
  52. ROYER DJ, Gurung HR, Jinkins JK, Geltz JJ, et al
    A Highly Efficacious HSV-1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology Via Humoral Immunity.
    J Virol. 2016 Mar 30. pii: JVI.00517.
    PubMed     Text format     Abstract available


  53. LE GRAND R, Bosquet N, Dispinseri S, Gosse L, et al
    Superior efficacy of an HIV vaccine combined with ARV prevention in SHIV challenged non-human primates.
    J Virol. 2016 Mar 23. pii: JVI.00230.
    PubMed     Text format     Abstract available


  54. JULIK E, Reyes-Del Valle J
    Generation of a more immunogenic measles vaccine by increasing its hemagglutinin expression.
    J Virol. 2016 Mar 16. pii: JVI.00348.
    PubMed     Text format     Abstract available


  55. HOLZER B, Hodgson S, Logan N, Willett B, et al
    Protection of cattle against rinderpest by vaccination with wild type but not attenuated strains of peste des petits ruminants virus.
    J Virol. 2016 Mar 16. pii: JVI.00040.
    PubMed     Text format     Abstract available


  56. SUTTON MS, Burns CM, Weiler AM, Balgeman AJ, et al
    Vaccination with live attenuated SIV protects from mucosal, but not necessarily intravenous, challenge with a minimally heterologous SIV.
    J Virol. 2016 Mar 9. pii: JVI.00192.
    PubMed     Text format     Abstract available


  57. SINGH K, Gittis AG, Gitti RK, Ostazeski SA, et al
    The vaccinia virus H3 envelope protein, a major target of neutralizing antibodies, exhibits a glycosyltransferase fold and binds UDP-Glucose.
    J Virol. 2016 Mar 2. pii: JVI.02933.
    PubMed     Text format     Abstract available


  58. IWASAKI M, Cubitt B, Sullivan BM, de la Torre JC, et al
    The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
    J Virol. 2016;90:3187-97.
    PubMed     Text format     Abstract available


    February 2016
  59. RUSSELL RF, McDonald JU, Lambert L, Tregoning JS, et al
    Use of the microparticle Nano-SiO2 as an adjuvant to boost vaccine immune responses in neonatal mice against influenza.
    J Virol. 2016 Feb 24. pii: JVI.03159.
    PubMed     Text format     Abstract available


  60. CARTER DM, Darby CA, LeFoley BC, Crevar CJ, et al
    Design and Characterization of a COBRA HA vaccine for H1N1 influenza viruses.
    J Virol. 2016 Feb 24. pii: JVI.03152.
    PubMed     Text format     Abstract available


  61. HUTIN S, Ling WL, Round A, Effantin G, et al
    Domain organization of vaccinia virus helicase-primase D5.
    J Virol. 2016 Feb 24. pii: JVI.00044.
    PubMed     Text format     Abstract available


  62. KAEVER T, Matho MH, Meng X, Crickard L, et al
    Linear epitopes in A27 are targets of protective antibodies induced by vaccination against smallpox.
    J Virol. 2016 Feb 17. pii: JVI.02878.
    PubMed     Text format     Abstract available


  63. ASBACH B, Kliche A, Kostler J, Perdiguero B, et al
    Streamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    J Virol. 2016 Feb 10. pii: JVI.03135.
    PubMed     Text format     Abstract available


  64. PROVINE NM, Badamchi-Zadeh A, Bricault CA, Penaloza-MacMaster P, et al
    Transient CD4+ T cell depletion results in the delayed development of functional vaccine-elicited antibody responses.
    J Virol. 2016 Feb 10. pii: JVI.00039.
    PubMed     Text format     Abstract available


  65. DIAZ-SAN SEGUNDO F, Medina GN, Ramirez-Medina E, Velazquez-Salinas L, et al
    Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response.
    J Virol. 2015;90:1298-310.
    PubMed     Text format     Abstract available


  66. YEN LC, Liao JT, Lee HJ, Chou WY, et al
    The C Terminus of the Core beta-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.
    J Virol. 2015;90:1178-89.
    PubMed     Text format     Abstract available


    January 2016
  67. NISHIYAMA S, Lokugamage N, Ikegami T
    The L-, M- and S-segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype.
    J Virol. 2016 Jan 27. pii: JVI.02241.
    PubMed     Text format     Abstract available


  68. GOLDEN JW, Maes P, Kwilas SA, Ballantyne J, et al
    Glycoprotein-specific antibodies produced by DNA vaccination protect guinea pigs from lethal Argentine and Venezuelan hemorrhagic fever.
    J Virol. 2016 Jan 20. pii: JVI.02969.
    PubMed     Text format     Abstract available


  69. SEN N, Arvin AM
    Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.
    J Virol. 2016;90:3284-7.
    PubMed     Text format     Abstract available


  70. CHEN CJ, Ermler ME, Tan GS, Krammer F, et al
    Influenza A viruses expressing intra- or inter-group chimeric hemagglutinins.
    J Virol. 2016 Jan 13. pii: JVI.03060.
    PubMed     Text format     Abstract available


  71. PATIL S, Kumar R, Deshpande S, Samal S, et al
    Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in V1 Loop.
    J Virol. 2016 Jan 13. pii: JVI.03090.
    PubMed     Text format     Abstract available


  72. DINIS JM, Florek NW, Fatola OO, Moncla LH, et al
    Deep sequencing reveals potential antigenic variants at low frequency in influenza A-infected humans.
    J Virol. 2016 Jan 6. pii: JVI.03248.
    PubMed     Text format     Abstract available


  73. TAO X, Garron T, Agrawal AS, Algaissi A, et al
    Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
    J Virol. 2015;90:57-67.
    PubMed     Text format     Abstract available


    December 2015
  74. GODI A, Facchetti A, Bissett SL, Cocuzza C, et al
    Naturally-Occurring Major and Minor Capsid Protein Variants of HPV45: Differential Recognition by Cross-Neutralizing Antibodies Generated by the HPV Vaccines.
    J Virol. 2015 Dec 30. pii: JVI.02859.
    PubMed     Text format     Abstract available


  75. CHENG C, Pancera M, Bossert A, Schmidt SD, et al
    Immunogenicity of a Prefusion HIV-1-Envelope Trimer in Complex with a Quaternary-Specific Antibody.
    J Virol. 2015 Dec 30. pii: JVI.02380.
    PubMed     Text format     Abstract available


  76. NACHBAGAUER R, Miller MS, Hai R, Ryder AB, et al
    Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets.
    J Virol. 2015 Dec 30. pii: JVI.02481.
    PubMed     Text format     Abstract available


  77. URBANOWICZ RA, McClure CP, Brown RJ, Tsoleridis T, et al
    A diverse panel of Hepatitis C Virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance.
    J Virol. 2015 Dec 23. pii: JVI.02700.
    PubMed     Text format     Abstract available


  78. DHANWANI R, Zhou Y, Huang Q, Verma V, et al
    A novel live Pichinde virus-based vaccine vector induces enhanced humoral and cellular immunity upon a booster dose.
    J Virol. 2015 Dec 16. pii: JVI.02705.
    PubMed     Text format     Abstract available


  79. COX A, Dewhurst S
    A single mutation at PB1 residue 319 dramatically increases the safety of PR8 LAIV in a murine model without compromising vaccine efficacy.
    J Virol. 2015 Dec 16. pii: JVI.02723.
    PubMed     Text format     Abstract available


  80. RYDER AB, Nachbagauer R, Buonocore L, Palese P, et al
    Vaccination with VSV-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains.
    J Virol. 2015 Dec 16. pii: JVI.02598.
    PubMed     Text format     Abstract available


  81. SMITH SA, Kilgore KM, Kasturi SP, Pulendran B, et al
    Signatures in SIVsmE660 Envelope gp120 are Associated with Mucosal Transmission but not Vaccination Breakthrough in Rhesus Macaques.
    J Virol. 2015 Dec 16. pii: JVI.02711.
    PubMed     Text format     Abstract available


  82. BECK Y, Fritz R, Orlinger K, Kiermayr S, et al
    Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.
    J Virol. 2015 Dec 9. pii: JVI.02985.
    PubMed     Text format     Abstract available


  83. VU HL, Ma F, Laegreid WW, Pattnaik AK, et al
    A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.
    J Virol. 2015;89:12070-83.
    PubMed     Text format     Abstract available


    November 2015
  84. HO TH, Kew C, Lui PY, Chan CP, et al
    PACT- and RIG-I-dependent activation of type I interferon production by a defective-interfering RNA derived from measles virus vaccine.
    J Virol. 2015 Nov 25. pii: JVI.02161.
    PubMed     Text format     Abstract available


  85. VAN DER SANDEN SM, Wu W, Dybdahl-Sissoko N, Weldon WC, et al
    Engineering Enhanced Vaccine Cell Lines to Eradicate Vaccine-Preventable Diseases: The Polio Endgame.
    J Virol. 2015 Nov 18. pii: JVI.01464.
    PubMed     Text format     Abstract available


  86. KHATTAR SK, DeVico AL, LaBranche CC, Panda A, et al
    Enhanced immune responses to HIV-1 envelope elicited by a vaccine regimen consisting of priming with Newcastle disease virus expressing HIV gp160 and boosting with gp120 and SOSIP gp140 proteins.
    J Virol. 2015 Nov 18. pii: JVI.02847.
    PubMed     Text format     Abstract available


  87. KOMA T, Patterson M, Huang C, Seregin AV, et al
    Machupo virus expressing GPC of the Candid#1 vaccine strain of Junin virus is highly attenuated and immunogenic.
    J Virol. 2015 Nov 18. pii: JVI.02615.
    PubMed     Text format     Abstract available


  88. WANG K, Goodman KN, Li DY, Raffeld M, et al
    An Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism is Superior to HSV-2 gD Subunit Vaccine to Protect Animals from Challenge with HSV-2.
    J Virol. 2015 Nov 11. pii: JVI.01845.
    PubMed     Text format     Abstract available


  89. HUANG SW, Tai CH, Fonville JM, Lin CH, et al
    Mapping Enterovirus A71 Antigenic Determinants from Viral Evolution.
    J Virol. 2015;89:11500-6.
    PubMed     Text format     Abstract available


  90. GANDAR F, Wilkie GS, Gatherer D, Kerr K, et al
    The Genome of a Tortoise Herpesvirus (Testudinid Herpesvirus 3) Has a Novel Structure and Contains a Large Region That Is Not Required for Replication In Vitro or Virulence In Vivo.
    J Virol. 2015;89:11438-56.
    PubMed     Text format     Abstract available


    October 2015
  91. BRENNAN G, Kitzman JO, Shendure J, Geballe AP, et al
    Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification.
    J Virol. 2015;89:9986-97.
    PubMed     Text format     Abstract available


    September 2015
  92. HYAKUMURA M, Walsh R, Thaysen-Andersen M, Kingston NJ, et al
    Modification of the asparagine-linked glycan density for the design of hepatitis B virus (HBV) virus-like particles with enhanced immunogenicity.
    J Virol. 2015 Sep 2. pii: JVI.01123.
    PubMed     Text format     Abstract available


    August 2015
  93. FAN RL, Valkenburg SA, Wong CK, Li OT, et al
    Generation of live attenuated influenza virus using codon usage bias.
    J Virol. 2015 Aug 12. pii: JVI.01443.
    PubMed     Text format     Abstract available


  94. KIM SM, Park JH, Lee KN, Kim SK, et al
    Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs.
    J Virol. 2015;89:8267-79.
    PubMed     Text format     Abstract available


  95. O'DONNELL V, Holinka LG, Krug PW, Gladue DP, et al
    African Swine Fever Virus Georgia 2007 with a Deletion of Virulence-Associated Gene 9GL (B119L), when Administered at Low Doses, Leads to Virus Attenuation in Swine and Induces an Effective Protection against Homologous Challenge.
    J Virol. 2015;89:8556-66.
    PubMed     Text format     Abstract available


    June 2015
  96. WISE MC, Hutnick NA, Pollara J, Myles DJ, et al
    An enhanced synthetic multi-clade DNA prime induces improved cross-clade reactive functional antibodies when combined with an adjuvanted protein boost in non-human primates.
    J Virol. 2015 Jun 17. pii: JVI.00652.
    PubMed     Text format     Abstract available


  97. GARCIA-ARRIAZA J, Perdiguero B, Heeney J, Seaman M, et al
    Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates.
    J Virol. 2015 Jun 3. pii: JVI.01265.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: